These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 8237268)

  • 1. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
    Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
    Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
    Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery.
    Madi-Jebara SN; Sleilaty GS; Achouh PE; Yazigi AG; Haddad FA; Hayek GM; Antakly MC; Jebara VA
    J Cardiothorac Vasc Anesth; 2004 Feb; 18(1):59-63. PubMed ID: 14973801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin treatment in haemodialysis patients with iron overload.
    el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
    Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
    Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
    PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A; Green PJ; Lee HA
    Clin Lab Haematol; 1991; 13(3):251-3. PubMed ID: 1794227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.
    Arndt U; Kaltwasser JP; Gottschalk R; Hoelzer D; Möller B
    Ann Hematol; 2005 Mar; 84(3):159-66. PubMed ID: 15565327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy.
    Biesma DH; Van de Wiel A; Beguin Y; Kraaijenhagen RJ; Marx JJ
    Eur J Clin Invest; 1994 Jun; 24(6):426-32. PubMed ID: 7957497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
    Webb L; Gilg J; Wilkie M
    Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
    Lin CL; Hsu PY; Yang HY; Huang CC
    Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.
    Chuang CL; Liu RS; Wei YH; Huang TP; Tarng DC
    Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
    de Sousa FT; Prata MM; Barbas JV; dos Santos JP
    Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
    Axelsson J; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2005 Oct; 46(4):628-34. PubMed ID: 16183417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].
    Borawski J; Mazerska M; Pawlak K; Myśliwiec M
    Pol Arch Med Wewn; 1994; 92 Spec No():14-20. PubMed ID: 7731894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.